title: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Jackman
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Holmes
authors.forename: Neal
authors.initials: N
authors.lastname: Lindeman
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Santosh
authors.initials: S
authors.lastname: Kesari
authors.forename: Ana M
authors.initials: AM
authors.lastname: Borras
authors.forename: Christopher
authors.initials: C
authors.lastname: Bailey
authors.forename: Francisca
authors.initials: F
authors.lastname: de Jong
authors.forename: Pasi A
authors.initials: PA
authors.lastname: Jänne
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Johnson
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib